PT-141 (bremelanotide) is a Melanotan-2-derived research peptide with melanocortin-receptor selectivity favouring MC4R. Full Kiwi Peps research profile.
The PT-141 peptide (bremelanotide, formerly PT-141) is a synthetic peptide derived from Melanotan 2, engineered for MC4R-preferential melanocortin-receptor agonism. Published research literature characterises both its pharmacokinetic profile and its endpoints in rodent behavioural assay models. In melanocortin research panels, PT-141 is the reference compound whenever MC4R selectivity is the variable of interest.
PT-141 peptide at a glance
| Attribute | Specification |
|---|---|
| Sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Molecular weight | ~1,025.2 Da |
| Class | Cyclic melanocortin analog (Melanotan-2 derivative) |
| Primary receptor | MC4R (with residual MC1R/MC3R activity) |
| Documented purity spec | ≥ 98% HPLC |
- Batch identifier and synthesis date traceable to the lot record
- HPLC purity ≥98% (typically ≥99% for peptides under 30 residues)
- LC-MS confirmed monoisotopic or average mass within ±0.5 Da of theoretical
- Counterion identity and content (acetate or trifluoroacetate) reported
- Bacterial endotoxin and residual solvents per the analytical method
PT-141 peptide FAQ
What is the PT-141 peptide?
PT-141 (bremelanotide) is a cyclic Melanotan-2-derived peptide engineered for MC4R-preferential melanocortin-receptor activation.
How is PT-141 different from Melanotan 2?
Melanotan 2 is non-selective across MC1R–MC5R. PT-141 is engineered for MC4R-preferential activity, which is why it is the reference compound in MC4R-selective research panels.
Where can New Zealand researchers buy the PT-141 peptide?
Kiwi Peps supplies PT-141 at ≥98% HPLC purity with third-party COA and same-day domestic dispatch. Research use only.
